Pengaruh Kualitas Pelayanan dan Kualitas Produk Kredit Multiguna terhadap Kepuasan Nasabah Kredit pada PT. Bpr Hoki Cabang Denpasar

The purpose of this study was to determine the effect of quality of service and product quality multipurpose loans to credit customer satisfaction at PT. BPR Hoki Region Denpasar. This study used a qualitative research using surveys and questionnaires to 85 respondents customers multipurpose loans PT. BPR Hoki Region Denpasar. The sampling technique uses accidental sampling. Data analysis techniques used in this research is multiple linear regression. It was found that the quality of service and quality of products simultaneously affect the customer satisfaction at PT. BPR Hoki Denpasar. Second, the quality of service and significant positive effect on customer satisfaction at PT BPR Hoki Denpasar. Finally, quality products and a significant positive effect on customer satisfaction at PT BPR Hockey Denpasar

Effect of Work Environment, Quality of System and Work Culture on Satisfaction of Accounting Information System User

The purpose of this study to explain the empirical evidence of the influence of the work environment, the quality of IT systems and work culture on the satisfaction of users of accounting information systems at PT XYZ. Sampling in this study uses nonprobability sampling methods that use criteria that employees who are sampled are employees using IT systems in his work with saturated sampling techniques, data was collected using a survey method with questionnaire techniques with respondents were employees at PT XYZ by analyzing the data using multiple linear regression. 216 questionnaires were distributed but only 124 questionnaires could be processed. The research results show that the work environment influences the satisfaction of cash system users, IT system quality influences the satisfaction of cash system users and work culture influences the satisfaction of cash system users. The results of hypothesis testing provide a synthesis that the better the work environment, the quality of IT systems and work culture, then the satisfaction of cash system users produced by employees at PT XYZ will be better too

Strategi Pengembangan Rekam Medis Elektronik di Instalasi Rawat Jalan RSUD Gambiran Kota Kediri

Pelayanan kesehatan di Indonesia dihadapkan pada era disrupsi. Kementerian Kesehatan Indonesia dalam upaya menghadapi era disrupsi pada program pembinaan pelayanan kesehatan rujukan diantaranya dengan mentargetkan pada tahun 2024 seluruh rumah sakit di Indonesia telah menerapkan rekam medis elektronik (RME) terintegrasi serta pengembangan pertukaran resume medis online antar rumah sakit. RME merupakan bagian dari aplikasi sistem informasi manajemen rumah sakit (SIMRS) yang terus dikembangkan. RSUD Gambiran telah menggunakan SIMRS untuk RME, namun penggunaannya belum optimal. Tujuan kegiatan pengabdian masyarakat ini adalah menganalisa strategi pengembangan SIMRS untuk RME di instalasi rawat jalan RSUD Gambiran Kota Kediri. Kegiatan dilakukan melalui wawancara mendalam dan observasi langsung, kemudian melakukan analisa fishbone untuk menentukan faktor-faktor penyebab masalah, menentukan prioritas penyelesaian masalah dengan analisa USG (urgency, seriousness, growth) dilanjutkan penyusunan strategi dengan analisa SWOT (strength, weakness, opportunity, threats). Faktor sumber daya manusia dan organisasi menjadi faktor utama yang mendukung keberhasilan penerimaan teknologi di rumah sakit. Manfaat dari kegiatan ini adalah dapat mengidentifikasi strategi pengembangan SIMRS untuk RME di instalasi rawat jalan RSUD Gambiran Kota Kediri. Penyusunan regulasi tatacara dan alur penggunaan SIMRS untuk RME merupakan strategi yang dapat diterapkan pada kegiatan pengabdian masyarakat saat ini

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma

Background: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAF(V600)-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported.Methods: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline and >= 1 time point thereafter constituted the analysis population. Change from baseline >= 10 points was considered clinically meaningful.Results: Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains were also comparable between arms. A transient deterioration in role function in cycle 1 day 15 (C1D15; -14.7 points) in the P+V arm and improvement in insomnia in the C+V arm at C2D15 (-12.4 points) was observed. Among patients who experienced a >= 10-point change from baseline (responders), between-group differences were greatest for insomnia (16%), social functioning (10%), fatigue (9%) and pain (7%), all favouring C+V. Diarrhoea, photosensitivity reaction, pyrexia, and rash did not meaningfully affect global health status (GHS). Serous retinopathy was associated with a transient decrease in GHS at C1D15 assessment.Conclusions: In patients with advanced/metastatic BRAFV600-mutated melanoma, treatment with C+V maintained HRQOL compared with P+V, with superior efficacy

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

Background: In the phase III double-blind European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 trial, pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with stage III cutaneous melanoma with complete resection of lymph nodes. In the pembrolizumab group, the incidence of grade I–V and of grade III–V immune-related adverse events (irAEs) was 37% and 7%, respectively. Methods: Patients were randomised to receive intravenous (i.v.) pembrolizumab 200 mg (N = 514) or placebo (N = 505) every 3 weeks, up to 1 year. On recurrence, patients could enter part 2 of the study: pembrolizumab 200 mg i.v. every 3 weeks up to 2 years, for crossover (those who received placebo) or rechallenge (those who had recurrence ≥6 months after completing 1-year adjuvant pembrolizumab therapy). For these patients, we present the safety profile and efficacy outcomes. Results: At the clinical cut-off (16-Oct-2020), in the placebo group, 298 patients had a disease recurrence, in which 155 (52%) crossed over (‘crossover’). In the pembrolizumab group, 297 patients completed the 1-year treatment period; 47 had a recurrence ≥6 months later, in which 20 (43%) entered the rechallenge part 2 (‘rechallenge’). In the crossover group, the median progression-free survival (PFS) was 8.5 months (95% confidence interval [CI] 5.7–15.2) and the 3-year PFS rate was 32% (95% CI 25–40%). Among 80 patients with stage IV evaluable disease, 31 (39%) had an objective response: 14 (18%) patients with complete response (CR) and 17 (21%) patients with partial response. The 2-year PFS rate from response was 69% (95% CI 48–83%). In the rechallenge group, the median PFS was 4.1 months (95% CI 2.6–NE). Among 9 patients with stage IV evaluable disease, 1 had an objective response (CR). Among the 175 patients, 51 (29%) had a grade I–IV irAE and 11 (6%) had a grade III–IV irAE. Conclusions: Pembrolizumab treatment after crossover yielded an overall 3-year PFS rate of 32% and a 39% ORR in evaluable patients, but the efficacy (11% ORR) was lower in those rechallenged

Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells.

An amendment to this paper has been published and can be accessed via a link at the top of the paper